PKC η Inhibitors
PKC η inhibitors represent a class of chemicals that play a crucial role in modulating the activity of protein kinase C eta (PKC η), a member of the PKC family of serine/threonine kinases. These inhibitors act through various mechanisms, primarily by directly binding to PKC η and inhibiting its kinase activity. One prominent example is Gö 6983, which selectively targets PKC isoforms, including PKC η, by binding to the ATP-binding site of the kinase. This binding blocks PKC η from undergoing activation and participating in downstream signaling events. Similarly, Enzastaurin and Sotrastaurin act as ATP-competitive inhibitors, specifically targeting PKC η, thereby interfering with its kinase activity. Staurosporine, a broad-spectrum protein kinase inhibitor, also effectively inhibits PKC η by competing with ATP for binding to the kinase's active site. In contrast, Bisindolylmaleimide I and Bisindolylmaleimide V belong to the bisindolylmaleimide family of PKC inhibitors and exert their inhibitory effects by directly binding to PKC η's ATP-binding site, interfering with its kinase activity. Ro 31-8220 is another potent PKC inhibitor that targets PKC η and other isoforms by competing with ATP for binding.
Chelerythrine, a natural alkaloid compound, acts as a PKC inhibitor, including PKC η, by binding to the catalytic domain of the kinase. Similarly, Rottlerin, a polyphenolic compound, selectively inhibits PKC δ but can also affect PKC η by interacting with the regulatory domain of the kinase. GF 109203X, a broad-spectrum PKC inhibitor, effectively targets PKC η by competing with ATP for binding to the kinase's active site. These PKC η inhibitors serve as valuable tools for researchers to investigate the role of PKC η in various cellular processes and signaling pathways. Overall, PKC η inhibitors offer valuable insights into the functional roles of PKC η and its involvement in diverse cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
Gö 6983 is a selective inhibitor of PKC isoforms, including PKC η. It binds to the ATP-binding site of PKC, preventing its activation and subsequent downstream signaling. Gö 6983 effectively inhibits PKC η activity by directly targeting the kinase. | ||||||
Enzastaurin | 170364-57-5 | sc-364488 sc-364488A sc-364488B | 10 mg 50 mg 200 mg | $254.00 $600.00 $1687.00 | 3 | |
Enzastaurin is a small molecule inhibitor of PKC β and PKC η. It acts by binding to the ATP-binding pocket of PKC, thereby inhibiting its kinase activity. By specifically targeting PKC η, Enzastaurin can modulate PKC η-mediated signaling pathways. | ||||||
Sotrastaurin | 425637-18-9 | sc-474229 sc-474229A | 5 mg 10 mg | $300.00 $540.00 | ||
Sotrastaurin is an ATP-competitive inhibitor of PKC η. It interacts with the ATP-binding site of PKC η, leading to the inhibition of its kinase activity. This direct inhibition can effectively modulate PKC η-dependent signaling cascades. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor, including PKC η. It competes with ATP for binding to the kinase's active site, leading to PKC η inhibition. Staurosporine directly modulates PKC η activity. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I is a potent PKC inhibitor that targets various isoforms, including PKC η. By binding to the ATP-binding site of PKC η, it directly inhibits the kinase activity and downstream signaling pathways associated with PKC η. | ||||||
Bisindolylmaleimide V | 113963-68-1 | sc-202080 sc-202080A | 1 mg 5 mg | $49.00 $168.00 | 1 | |
Bisindolylmaleimide V is another member of the bisindolylmaleimide family of PKC inhibitors. It targets PKC η and other isoforms by binding to the ATP-binding site, effectively inhibiting PKC η-mediated signaling pathways. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $90.00 $240.00 | 17 | |
Ro 31-8220 is a potent PKC inhibitor that directly interacts with PKC η and other isoforms. It competes with ATP for binding to the kinase's active site, leading to the inhibition of PKC η kinase activity. | ||||||
DAPH-7 | 145915-60-2 | sc-200699 | 1 mg | $71.00 | 1 | |
DAPH-7 is a selective PKC inhibitor that targets PKC η. It binds to the ATP-binding pocket of PKC η, inhibiting its kinase activity and interfering with PKC η-dependent signaling events. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
Chelerythrine is a natural alkaloid compound that acts as a PKC inhibitor, including PKC η. It binds to the catalytic domain of PKC η, preventing its activation and downstream signaling. | ||||||
Rottlerin | 82-08-6 | sc-3550 sc-3550B sc-3550A sc-3550C sc-3550D sc-3550E | 10 mg 25 mg 50 mg 1 g 5 g 20 g | $82.00 $163.00 $296.00 $2050.00 $5110.00 $16330.00 | 51 | |
Rottlerin is a polyphenolic compound that selectively inhibits PKC δ, but it can also affect other PKC isoforms, including PKC η. It interacts with the regulatory domain of PKC η, inhibiting its activity and modulating PKC η-dependent pathways. | ||||||